Barron's Names LLY Among 11 Healthcare Stocks to Buy
What happened
Barron's published a sector screen identifying Eli Lilly and ten other healthcare names — including McKesson — as overlooked buying candidates following a period of relative underperformance in the sector. The piece frames healthcare as a group that has fallen out of favor with the broader market. No new company-specific financial disclosures, earnings data, or guidance changes were reported alongside the recommendation.
The QL Read
QuantLogix carries LLY at a composite 62/100 (Buy) with shares up 0.92% intraday to $1,169.86. Market breadth is marginally positive at 51.2% advancing, a neutral-to-mildly-supportive backdrop for a sector-rotation call rather than a high-conviction momentum setup.
Not financial advice. QuantLogix is a research platform; nothing in this brief constitutes a recommendation to buy or sell any security. We summarize public news with attribution to the original publisher; visit the source above for the full original article.